Hem/Onc News

Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]

Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions

  Abstract: Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

  H&O  What type of drug is zanubrutinib? CT  Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]